MedImmune boosts cancer R&D pipeline with potential $440M Spirogen buy

10/15/2013 | Reuters

AstraZeneca's MedImmune unit agreed to acquire Spirogen, a privately held biotech firm focused on antibody-drug conjugate technology, for $200 million upfront plus $240 million in milestone fees as part of efforts to strengthen its oncology research and development pipeline. The agreement includes a $20 million equity investment in Switzerland's ADC Therapeutics, which has a licensing deal with Spirogen. ADC's and Spirogen's technologies will allow MedImmune to "accelerate antibody-drug conjugates into the clinic," MedImmune Executive Vice President Bahija Jallal said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC